沙库巴曲缬沙坦应用于心力衰竭的研究进展
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v2i4.2640
Abstract
心力衰竭是各类心血管疾病的终末阶段,尽管应用临床指南推荐疗法,但患者预后仍较差。血管紧张素受体脑啡肽酶抑制剂沙库巴曲缬沙坦是心力衰竭治疗领域的一种新型药物,因其使用在治疗中的卓越疗效,受到人们的广泛关注。现就沙库巴曲缬沙坦作用机制、临床研究结果、临床指南推荐等作一综述。
Keywords
心力衰竭；沙库巴曲缬沙坦；脑啡肽酶；综述
Full Text
PDF - Viewed/Downloaded: 0 TimesIndexation
Download Index RecordReferences
[1] Mcmurray J J V,Packer M,Desai A S,et al.The PARADIGM-HF Investigators andCommittees.Angiotensin-neprilysin inhibition versus enalapril in heart failure[J].New England Journal of Medicine,2014,371(11).
[2] Srikanth Y , Aronow W S , Pratik M , et al. The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan[J].Archives of Medical
[3] Buggey J,Mentz R J,Devore A D, et al. Angiotensin Receptor Neprilysin Inhibition in Heart Failure:Mechanistic
[4] Fu S , Ping P , Wang F , et al. Synthesis,secretion,function,metabolism and application of natriuretic peptides in heart failure[J].Journal of Biological Engineering,2018,12(1):2.
[5] Senni M ,Mcmurray J J V, Wachter R,et al.Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION,a double‐blind, randomized comparison of two uptitration regimens
[6] Hegde L G , Yu C , Madhavi C , et al. Comparative efficacy of AHU-377, a potent neprilysin inhibitor, in two rat models of volume-dependent hypertension[J]. BMC Pharmacology,
[7] 陆再英,钟南山.内科学.第7版[M].人民卫生出版社,2008:167-175.
[8] Solomon S D , Zile M , Pieske B,et al.The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.[J].Lancet,2012,380(9851):1387-1395.
[9] Solomon S D , Rizkala A R , Gong J,et al.Angiotensin receptor neprilysin
[2] Srikanth Y , Aronow W S , Pratik M , et al. The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan[J].Archives of Medical
[3] Buggey J,Mentz R J,Devore A D, et al. Angiotensin Receptor Neprilysin Inhibition in Heart Failure:Mechanistic
[4] Fu S , Ping P , Wang F , et al. Synthesis,secretion,function,metabolism and application of natriuretic peptides in heart failure[J].Journal of Biological Engineering,2018,12(1):2.
[5] Senni M ,Mcmurray J J V, Wachter R,et al.Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION,a double‐blind, randomized comparison of two uptitration regimens
[6] Hegde L G , Yu C , Madhavi C , et al. Comparative efficacy of AHU-377, a potent neprilysin inhibitor, in two rat models of volume-dependent hypertension[J]. BMC Pharmacology,
[7] 陆再英,钟南山.内科学.第7版[M].人民卫生出版社,2008:167-175.
[8] Solomon S D , Zile M , Pieske B,et al.The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.[J].Lancet,2012,380(9851):1387-1395.
[9] Solomon S D , Rizkala A R , Gong J,et al.Angiotensin receptor neprilysin
Copyright © 2020 尚小童, 刘晓堃
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License